being first doesn't mean much long term. Who remembers the first internet outfit? You need to be old enough and have a good memory.
" This company has a very low float, not so good if Mutual Funds & Institutions are lined up wanting to absorb hundreds of millions of shares and the company does not have those shares. Answer to that is, increase company shares by hundreds of millions. That's called diluting shares. So much for that $20.00 Parabolic milestone deal. "
CAN YOU BELIEVE WHAT HE IS SAYING? FACEBOOK, GOOGLE, MICROSOFT, ETC. ETC. ALL WENT THRU THIS PROCESS WHEN DISCOVERED. AND WHEN IT;S EDAP'S TURN IT'S CALLED DILUTION.
The dream of any shareholders are for institutions and mutual funds to line up and not have enough shares.
For those that are bullish like me only. If you are looking at the 4th Quarter as the breakout period this isa heck of a buying opportunity. I know we all know the 3rdq vs 4thq arguments but fast money can't wait 3 months. I
1.We don't need to know how many shares you have or don't have. I at least don't care.
2.We don't need clueless price predictions. 40 would be nice but let's break the 6.50 target price first.
I am very bullish on this stock based on the technology and business model.
If you have dig that deep to find that analyst then it is not worthwhile.
Compare this stock to Mankind mnkd
mnkd got fda approval then tanked
edap got approval but retraced a little
mnkd business model stunk and were not able to generate sales even after partnering with Sanofi
edap on it's own has already announced sales in addition to their world wide market penetration
mankd had lots of coverage and exposure due to their celebrity chair Alfred mann
edap has little or no coverage or exposure yet
I think hedge and mutual funds are sneakily and slowly loading up before announcing coverage.
They want to buy at these low prices because they have to constantly show quarterly profits to their shareholders
We all know EDAP is worth $10 and will eventually get to 10. The question is do we sell at 10 or wait for higher and how long do we need to wait for it to get higher given our patience with this stock. I have lost a lot of opportunities being in this stock for close to 2 years but would like to be rewarded beyond $10 a share.
CHARLOTTE, N.C., OCTOBER 13, 2015 -- SonaCare Medical, LLC, a pioneer in minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance from the U.S. Food and Drug Administration (FDA) to market the Sonablate® 450 in the U.S. for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. SonaCare Medical expects to begin U.S. distribution this October.
"The FDA regulatory authorization to market Sonablate® in the U.S. is a milestone for non-invasive prostate care and a tremendous gain for men's health," said Mark Carol, MD, Chief Executive Officer of SonaCare Medical. "Men all over the world, in the more than 49 countries where it has already been authorized for use, have had access to this technology for prostate ablation. There are numerous peer reviewed articles attesting to its value in ablating the prostate while minimizing the occurrence of side effects. Our company is appreciative of the collaborative efforts made on the part of the FDA to bring this technology to the U.S."
Sonablate® trial investigator Michael Koch, MD, Chairman of the Department of Urology at Indiana University comments, "I believe that we are at a pivotal point in prostate care. Simultaneous advances in imaging, fusion technologies, and now more focused therapies are going to allow us to precisely diagnose prostate conditions, and ablate these targeted areas rather than perform whole gland prostate surgery, which carries a significant burden on quality of life. HIFU will become the work-horse of subtotal prostate therapy."
Herbert Lepor, MD, Professor and Martin Spatz Chairman, Department of Urology NYU School of Medicine, who also participated in the Sonablate® trial, further comments, "HIFU is a novel technology that has been used worldwide to ablate prostate tissue. Until now, this technology was not a
I don't particularly like Hillary but she is right that drugs are too expensive. If you think meds are cheap here in the U.S. you need to get your brain checked.